Apricus Biosciences Inc  

(Public, NASDAQ:APRI)   Watch this stock  
Find more results for APRI
0.950
-0.010 (-1.04%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.91 - 0.99
52 week 0.86 - 5.95
Open 0.93
Vol / Avg. 72,724.00/657,425.00
Mkt cap 12.01M
P/E     -
Div/yield     -
EPS -1.21
Shares 7.73M
Beta 0.69
Inst. own 26%
Aug 2, 2017
Q2 2017 Apricus Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2017
Q1 2017 Apricus Biosciences Inc Earnings Call - Webcast
May 11, 2017
Q1 2017 Apricus Biosciences Inc Earnings Release
Mar 13, 2017
Q4 2016 Apricus Biosciences Inc Earnings Call
Mar 13, 2017
Q4 2016 Apricus Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -128.98%
Operating margin - -232.64%
EBITD margin - -227.38%
Return on average assets -271.63% -119.11%
Return on average equity - -
Employees 15 -
CDP Score - -

Address

11975 El Camino Real Ste 300
SAN DIEGO, CA 92130-2543
United States - Map
+1-858-2228041 (Phone)
+1-858-4368155 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Officers and directors

Kleanthis G. Xanthopoulos Ph.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Richard W. Pascoe Chief Executive Officer, Principal Accounting Officer, Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Brian T. Dorsey Senior Vice President, Chief Development Officer
Age: 47
Bio & Compensation  - Reuters
Paul V. Maier Independent Director
Age: 68
Bio & Compensation  - Reuters
Rusty Ray Independent Director
Age: 45
Bio & Compensation  - Reuters
Sandford D. Smith Independent Director
Age: 69
Bio & Compensation  - Reuters
Wendell Wierenga Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters